Five Prime Therapeutics to Present Data From Healthy

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Five Prime Therapeutics to Present Data From Healthy Volunteer Cohorts in Phase 1 Trial of FPA008 at the 2014 ACR/ARHP Annual Scientific Meeting

SOUTH SAN FRANCISCO, Calif., Nov. 13, 2014 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq: FPRX ), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, announced that it will present results from the healthy volunteer cohorts in its Phase 1 clinical trial of FPA008, a monoclonal antibody that inhibits colony stimulating factor-1 receptor (CSF-1R). The results will be featured in a poster presentation titled "A Phase 1 Study of FPA008, an Anti-Colony Stimulating Factor 1 Receptor (anti-CSF-1R) Antibody in Healthy Volunteers and Subjects with Rheumatoid Arthritis (RA): Preliminary Results" at the 2014 American College of Rheumatology and the Association of Rheumatology Health Professionals (ACR/ARHP) Annual Scientific Meeting. The meeting is being held November 14-19, 2014 in Boston, Massachusetts, and the poster presentation is scheduled to take place on Monday, November 17 from 9:00 am to 11:00 am, with the poster viewable from 8:30 am to 4:00 pm. (Presentation Number 1493). The abstracts are available in the online meeting supplement: http://www.acrannualmeeting.org/wp-content/up...ement2.pdf .

"FPA008 was well-tolerated in healthy volunteer subjects at doses associated with modulation of key biomarkers. This important information will guide our dosing decisions as we move into patients with active disease," said Julie Hambleton, M.D., senior vice president and chief medical officer of Five Prime. "With the initial safety and dosing information from Parts 1 and 2 of the trial in hand, we are now ready to begin dosing RA patients who are on methotrexate to further assess tolerability and preliminary efficacy measures in Part 3. We will explore FPA008's ability to affect inflammation of the joints in RA patients with active disease, as measured by clinical signs and symptoms and magnetic resonance imaging (MRI) scores."

The Phase 1 clinical trial of FPA008 is a randomized, double-blind, placebo-controlled, single- and multiple-ascending dose study of FPA008 being conducting in three parts. In Part 1, eight healthy volunteers per dose cohort were randomized (3:1) to receive a single intravenous infusion of FPA008 (at dose levels of 0.2, 1, 3, or 10 mg/kg) or placebo. In Part 2, an additional eight healthy volunteers per dose cohort were randomized (3:1) to receive two doses of FPA008 or placebo administered 14 days apart, at 1 or 3 mg/kg. Dose escalation decisions were based on the incidence of dose limiting toxicities (DLTs) plus attributed adverse events (AEs) beyond the DLT period. Pharmacokinetic (PK), CD16+ monocytes, bone turnover markers, and serum concentrations of the CSF-1R ligands CSF1 and IL34 were assessed. Part 3 consists of an open-label evaluation of 3 dose levels in RA patients whose disease is not responding to methotrexate therapy. The primary endpoint of the trial is safety, with secondary endpoints including PK, pharmacodynamics (PD) and disease activity as measured by ACR scores and joint MRI.

Preliminary results from the healthy volunteer portion of the trial found that FPA008 is well tolerated in doses up to 3 mg/kg. Additionally, at all dose levels tested, Five Prime observed PD effects of suppression of non-classical CD16+ monocytes and a decrease of bone turnover biomarkers (CTx, Trap5), all of which may indicate the potential for clinical benefit in RA patients. The most common FPA008 treatment-related toxicities were pruritus, eyelid edema along with facial swelling, fatigue, and headache. These events were mild (Grade 1 or 2) and self-limited. Some dose-dependent elevations of CK, LDH, AST were observed but were not associated with clinical signs/symptoms, were reversible, and were expected due to FPA008-mediated inhibition of Kupffer cells responsible for removing these enzymes.

A copy of the poster will be available at http://www.fiveprime.com/news-media/publicati...sentations following the presentation.

Five Prime expects to begin enrolling RA patients in Part 3 of the study by year end. The Company also recently announced that it is expanding development of FPA008 into solid tumors and anticipates initiating a clinical trial in 2015.

About FPA008

FPA008, an antibody that inhibits colony stimulating factor-1 receptor (CSF-1R), is being developed by Five Prime to treat patients with monocyte-dependent diseases, including rheumatoid arthritis (RA) and solid tumors. FPA008 inhibits the activation and survival of monocytes and macrophages that produce cytokines and are elevated in RA and certain tumors. FPA008 also directly inhibits osteoclasts, monocyte-lineage cells that can cause bone erosions in patients with RA.

About Five Prime

Five Prime Therapeutics, Inc. discovers and develops innovative therapeutics to improve the lives of patients with serious diseases. Five Prime's comprehensive discovery platform, which encompasses virtually every medically relevant extracellular protein, positions it to explore pathways in cancer, inflammation and their intersection in cancer immunotherapy, an area of oncology with significant therapeutic potential and a growing focus of the company's R&D activities. Five Prime has entered into strategic collaborations with leading global pharmaceutical companies and has promising product candidates in clinical and late preclinical development. For more information, please visit www.fiveprime.com .

Cautionary Note on Forward-looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Five Prime's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include statements regarding Five Prime's potential receipt of milestone payments and royalties. Factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Five Prime's filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" contained therein. Except as required by law, Five Prime assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

Amy Kendall, Corporate Communications 415-365-5776

Scroll down for more posts ▼

Top 10 Most Recent News Articles

LG Channels UAE Push Tests the Free Streaming Model

Updated Category News Views 137

A television's idle screen is turning into contested real estate in the UAE. LG Channels is adding programming from Rakuten TV, Stingray and Red Bull TV to its free, ad-supported service, and that matters for more than somebody hunting a movie after dinner. This is a practical push to make webOS-powered screens more useful, more frequently used and, eventually, more...

Continue Reading
Condo Downsizing Demands More Than a Price Check Today

Updated Category News Views 58

A smaller front door can hide a surprisingly large stack of obligations. That is the useful point in the HelloNation guidance featuring Chevy Chase real estate expert Lise Howe: downsizing into a condo is not merely a square-footage trade. It is a decision about recurring costs, building stewardship, daily friction, and whether the place still works when life gets less...

Continue Reading
Housing's Value Equation Is Getting More Complicated

Updated Category News Views 58

A homeowner's insurance bill has become a louder market signal than a granite countertop. Green Builder Media's latest batch of research, publishing and events is aimed squarely at that uncomfortable truth: housing is no longer judged only by the price on the contract. Buyers, builders, lenders and insurers are being pushed to reckon with what a home costs to own, protect...

Continue Reading
Leqembi’s Real-World Data Gives BioArctic More Weight

Updated Category News Views 133

A Harder Look at Treatment Staying Power Alzheimer’s drug data rarely arrive without a thicket of caveats, and that is exactly why this Leqembi update deserves a calm read rather than a victory lap. BioArctic’s partner Eisai presented a three-year real-world analysis at CTAD 2026 covering 560 early Alzheimer’s patients across 13 U.S. sites. The headline is striking:...

Continue Reading
Yoodli's No. 9 Ranking Signals Enterprise AI Traction

Updated Category News Views 58

Ninth place can be easy to dismiss until you notice the company is sitting near the top of a 500-name growth list. Yoodli's No. 9 position on Deloitte's 2026 Technology Fast 500 is a meaningful signal that its AI-based coaching and workforce-skills pitch is getting traction inside large organizations. It is not a revenue disclosure, it is not a valuation marker, and...

Continue Reading
MetaOptics Tests a Real Path Into Secure Imaging Markets

Updated Category News Views 68

Fingerprint scanners have never impressed me much; fooling one is exactly the sort of nuisance that keeps security buyers spending. MetaOptics’ new collaboration with Hong Kong’s ASTRI goes after that uncomfortable problem with a compact nano-optics imaging system built for biometric security and smart sensing. It is a sensible target. It is also, at this stage, a...

Continue Reading
TGHL Eyes U.S. Battery Shift Through EnChem Merger

Updated Category News Views 159

A Policy Squeeze Is Rewriting the Battery Map Battery supply chains are getting shoved through a narrower gate, and that is exactly why this proposed deal deserves a hard look. The GrowHub Limited wants to acquire EnChem America, a Georgia-based lithium-ion battery electrolyte producer, and the timing is plainly built around Washington's push to reduce reliance on...

Continue Reading
Clarivate's 2026 Research List Carries a Trust Test

Updated Category News Views 254

Seven thousand ninety awards can look like a victory lap until you remember how easily raw citation counts can be gamed. Clarivate’s 2026 Highly Cited Researchers list is more interesting for its insistence on screening than for the familiar names at the top. In a research world where publication volume, self-citation and paper mills have made plenty of people...

Continue Reading
Mar-Jac's Safety Milestone Carries Real Operational Weight

Updated Category News Views 62

Four million worked hours without a lost-time accident is the sort of number that ought to make people pause, especially in poultry processing. Mar-Jac Poultry’s Gainesville facility earned Workplace Safety recognition from the Greater Hall Chamber of Commerce after reaching that mark, and this is one corporate achievement that deserves a little less eye-rolling than...

Continue Reading
Tim Hortons Bets on ELF Cheer for U.S. Holiday Visits

Updated Category News Views 35

Nothing says holiday restaurant marketing quite like putting spaghetti-shaped whipped topping on hot chocolate and trusting a 2003 movie to do the selling. Tim Hortons is rolling out an ELF-inspired menu at participating U.S. locations starting November 18, 2026, pairing the chain with Warner Bros. Consumer Products and mining Buddy the Elf's sugar-fueled world for a...

Continue Reading

Top 5 Most Recently Viewed Articles

T&T Supermarkets Expands Presence with New Store Opening

Updated Category News Views 466

T&T Supermarkets Unveils Plans for a Major New Store T&T Supermarket Inc., Canada's largest Asian grocery retailer, is excited to share plans for their newest store in California, which will be located at Crossroads Marketplace in Chino Hills. This store will span an impressive 61,000 square feet, providing ample space for a wide variety of products and services to meet...

Continue Reading
Autohome Inc. Unveils its Comprehensive 2024 ESG Report

Updated Category News Views 268

Autohome Inc. Releases 2024 ESG Report Autohome Inc. (NYSE: ATHM) has shared its 2024 Environmental, Social, and Governance (ESG) report. This document emphasizes the firm's commitment to sustainable practices and highlights their ongoing journey towards eco-friendly solutions within the automobile sector. Insights from the ESG Report The report details the extensive ESG...

Continue Reading
Nintendo and The Pokemon Company Pursue Legal Action Against Palworld

Updated Category News Views 87

Nintendo and The Pokemon Company Take Legal Action Nintendo and The Pokemon Company have officially initiated a patent infringement lawsuit against the creators of the popular survival adventure game, "Palworld." This development has caught the attention of both gamers and industry experts alike. Details of the Lawsuit Reports indicate that the lawsuit was filed on...

Continue Reading
NYCM Insurance Achieves Elite Winner Status for Wellness

Updated Category News Views 118

NYCM Insurance Celebrated for Wellness Excellence NYCM Insurance proudly announces its recognition as an "Elite Winner" among the Nation's Best and Brightest in Wellness. This marks an outstanding milestone for the company, achieving the accolade for the twelfth consecutive year, a testament to their dedication to enhancing employee wellness. Commitment to Employee...

Continue Reading
Antonio Filosa Leads Stellantis with Newly Formed Team

Updated Category News Views 284

New Leadership Structure at Stellantis Under Antonio Filosa Today marks a significant milestone for Stellantis N.V. as Antonio Filosa steps into the role of Chief Executive Officer. Alongside this transition, he has unveiled an exciting new leadership team, showcasing a strong lineup of industry veterans and decision-makers from across Stellantis’ diverse operations...

Continue Reading